01/09/2023
U.S. health regulators gave early approval to a new ’s drug from Eisai Co. and Biogen Inc., the most promising to date in a new class of medicines that may help slow cognitive decline caused by the disease.
Read more: https://www.wsj.com/articles/new-alzheimers-drug-approved-by-fda-promises-to-slow-disease-11673032312?st=qdke1zm55lbo8rm&reflink=desktopwebshare_permalink
By Joseph Walker via The Wall Street Journal
Eisai and Biogen’s Leqembi is the first drug to show that reducing a protein linked to Alzheimer’s helped patients.